Top Medical News
4 hours ago
Women who have a history of carbon monoxide poisoning (COP) appear to be at a lower risk of developing breast cancer, a recent Taiwan study has found. This points to a potential protective effect of CO against breast cancer.
A new fat-dissociation method (FM) of examining positive lymph nodes (LNs) from surgically removed mesentery reduces the overall time required for detection without sacrificing accuracy, a recent study has found.
Tristan Manalac, 2 days ago
Breast cancer patients face a high risk of skeletal-related events (SREs), particularly when diagnosed at advanced stages, reports a new Indonesia study presented at the recently concluded 2020 Asia Virtual Congress of the European Society of Medical Oncology (ESMO Asia 2020). Oncological and reproductive factors seem to affect this risk and may be worth monitoring for.
3 days ago
Exposure to valproic acid seems to reduce the risk of melanoma, a recent study has found. That this may be due to residual confounding cannot be ruled out, however.
Audrey Abella, 3 days ago
In a subgroup analysis of the phase IIIb CompLEEment-1 trial, ribociclib plus letrozole showed a manageable safety profile in Asian patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC).
Tristan Manalac, 3 days ago
While lung cancer is relatively rare among kidney transplant recipients, it remains a dangerous complication, carrying high rates of metastasis and mortality, according to a Philippine case series presented at the recently concluded 2020 Asia Virtual Congress of the European Society of Medical Oncology (ESMO Asia 2020)
3 days ago
Following treatment with nivolumab, a programmed death (PD)-1 inhibitor, the expression of inflammatory markers seems to correlate with better survival and treatment response in hepatocellular carcinoma (HCC) patients, a recent study has shown. This suggests that antitumour inflammatory mechanisms play a role in the action of nivolumab.
Special Reports
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

14 Aug 2019
Renal cell carcinoma (RCC) is the most common primary tumour arising from the kidney, constituting approximately 80–85% of primary renal neoplasms. According to the Malaysian National Cancer Registry Report 2007–2011, RCC accounts for 62.8% of all kidney cancers nationwide. RCC typically occurs approximately 50% more commonly in men compared with women, and predominantly occurs in the sixth to eighth decade of life.
30 Jan 2019
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Conference Reports
Natalia Reoutova, 25 Nov 2020

Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.

Roshini Claire Anthony, 12 Nov 2020

Women with HER2+ early breast cancer who achieved pathologic complete response (pCR) on neoadjuvant treatment had improved overall survival (OS) and event-free survival (EFS) outcomes, according to final analysis results of the phase III NeoALTTO, BIG 1-06 trial.

Roshini Claire Anthony, 11 Nov 2020

The use of an algorithm to identify the presence of coronary artery calcifications (CAC) during radiotherapy-planning CT scans may help assess cardiovascular disease (CVD) risk in women with breast cancer, according to a study from the Netherlands.

Dr Margaret Shi, 10 Nov 2020

A combined regimen of apatinib plus gefitinib as first-line treatment improves progression-free survival (PFS) vs placebo plus gefitinib in patients with advanced EGFR-mutant (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), results of the phase III ACTIVE study have shown.

Roshini Claire Anthony, 09 Nov 2020

The combination of nivolumab and cabozantinib in the first-line setting conferred greater survival outcomes and responses compared with sunitinib in patients with clear cell advanced renal cell carcinoma (RCC), results of the phase III CheckMate 9ER trial showed.

Roshini Claire Anthony, 06 Nov 2020

Adding abemaciclib to adjuvant endocrine therapy (ET) resulted in improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in women with hormone receptor (HR)+, HER2-negative, node-positive early breast cancer at high risk of recurrence, results of the phase III monarchE* trial showed.

Audrey Abella, 04 Nov 2020
The initial progression-free survival (PFS) improvement obtained with the addition of olaparib to bevacizumab was sustained beyond first progression, as reflected by the significant PFS2 benefit in women with newly diagnosed, advanced high‐grade ovarian cancer, according to the final PFS2 analysis of the phase III PAOLA-1*/ENGOT-ov25 trial.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download